Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15031625 | 0.90 | MEN1 (0.38) | L3MBTL1TDP1CA14HDAC1HDAC2 | |
| SCHEMBL3004120 | 0.90 | MEN1 (0.38) | L3MBTL1TDP1CA14HDAC1HDAC2 | |
| SCHEMBL30380807 | 0.90 | MEN1 (0.38) | L3MBTL1TDP1CA14HDAC1HDAC2 | |
| SCHEMBL30380313 | 0.90 | TDP1 (0.40) | L3MBTL1TDP1CA14HDAC1HDAC2 | |
| SCHEMBL13214411 | 0.85 | CA14 (0.34) | L3MBTL1CA14HDAC1HDAC2HDAC6 | |
| SCHEMBL3021763 | 0.85 | CA14 (0.34) | L3MBTL1CA14HDAC1HDAC2HDAC6 | |
| SCHEMBL27252284 | 0.83 | HDAC6 (0.39) | L3MBTL1TDP1CA14HDAC1HDAC2 | |
| SCHEMBL15031623 | 0.82 | L3MBTL1 (0.32) | L3MBTL1HDAC1HDAC2HDAC6 | |
| SCHEMBL13234354 | 0.82 | L3MBTL1 (0.32) | L3MBTL1HDAC1HDAC2HDAC6 | |
| SCHEMBL13911970 | 0.81 | ALDH1A1 (0.38) | L3MBTL1HDAC1HDAC2HDAC6THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512158-B2 | Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes | NEWLINK GENETICS CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| EP-2089051-B1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NEWLINK GENETICS (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9090643-B2 | Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes | NEWLINK GENETICS CORPORATION (US) | 2015-07-28 | — | — | US | disclosed |
| US-8916169-B2 | Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes | NEWLINK GENETICS CORPORATION (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130178613-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NewLink Genetics Corp. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130164318-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NewLink Genetics Corp. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130164319-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NewLink Genetics Corp. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8357777-B2 | Enhanced immunogenicity of tumor associated antigens by addition of αgal epitopes | NEWLINK GENETICS (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120003251-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NEWLINK GENETICS (US) | 2012-01-05 | — | — | US | disclosed |
| US-7998486-B2 | Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes | NEWLINK GENETICS CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2089051-A2 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | Newlink Genetics (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20090060930-A1 | Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes | NEWLINK GENETICS | 2009-03-05 | — | — | US | disclosed |
| WO-2008057235-A9 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NEWLINK GENETICS (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008057235-A2 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NEWLINK GENETICS (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130164319-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | ENGASE, FUT5, FUT6 | L3MBTL1 1511/4885TDP1 2062/4885CYP4F2 3908/4885 |
| US-20130178613-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | ENGASE, FUT5, FUT6 | L3MBTL1 1511/4885TDP1 2062/4885CYP4F2 3908/4885 |
| US-20090060930-A1 | Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes | ENGASE, FUT5, FUT6 | L3MBTL1 1511/4885TDP1 2062/4885CYP4F2 3908/4885 |
| US-20120003251-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | ENGASE, GALE, FUT5 | L3MBTL1 1731/4885TDP1 1435/4885CYP4F2 3057/4885 |
| US-20130164318-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | ENGASE, FUT5, FUT6 | L3MBTL1 1511/4885TDP1 2062/4885CYP4F2 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.